Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis

Abbreviations CR complete response CRC colorectal cancer CTLA-4 anti-cytotoxic T lymphocyte antigen-4 DCR disease control rate dMMR mismatch repair-deficient ICB immune checkpoint blockade MMR mismatch repair MSI microsatellite instability MSI-H microsatellite instability-high MSI-L microsatellite instability-low MSS microsatellite stable ORR objective response rate OS overall survival PD progression disease PD-1 programmed cell death protein-1 PFS progression-free survival pMMR mismatch repair-proficient PR partial response SD stable disease TRAE treatment-related adverse event Dear Editor, Colorectal cancer (CRC) is a common cancer in China and worldwide [ 1–2]. [...]36 (52.2%) patients were classified as dMMR/MSI-H, and 30 (43.5%) as pMMR/MSI-L/MSS. Univariate analysis showed that MMR/MSI status and immunotherapy setting were significantly associated with the objective response rate (ORR) and disease control rate (DCR). Abbreviations: OS, overall survival; PFS, progression-free survival; dMMR, mismatch repair-deficiency; MSI-H, microsatellite instability-high; pMMR, mismatch repair-proficient; MSI-L, microsatellite instability-low; MSS, microsatellite stable Univariate analysis for investigating the association between clinical factors and survival showed that dMMR/MSI-H status and early immunotherapy use were significantly associated with favorable OS (P < 0.001, P < 0.001) and PFS (P < 0.001, P < 0.001) (Supplementary Table S8, Figure 1C-F).